Anterix (ATEX) EPS (Weighted Average and Diluted) (2020 - 2025)

Anterix filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.35 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 185.37% to -$0.35 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.36, a 369.14% increase, with the full-year FY2025 number at -$0.61, down 24.49% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.35 in Q4 2025 for Anterix, down from $2.86 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.86 in Q3 2025 to a low of -$0.84 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.38 (2022), compared with a mean of -$0.04.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 1950.0% in 2024, down 727.27% in 2024.
  • Anterix's EPS (Weighted Average and Diluted) stood at -$0.69 in 2021, then soared by 39.13% to -$0.42 in 2022, then skyrocketed by 104.76% to $0.02 in 2023, then surged by 1950.0% to $0.41 in 2024, then crashed by 185.37% to -$0.35 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.35 (Q4 2025), $2.86 (Q3 2025), and $1.35 (Q2 2025) per Business Quant data.